0.5
0.5
800000
800000
17.50
29227745
14891046
1250000
29222746
1.00
1174640
29222746
3.63
1568125
3.63
1568125
1.76
100000000
0.0001
3238320
204829884
940594
2142779
0
3911635
142725025
828262
-62107781
2922
146636660
0
146371138
200447
146636660
143618247
27200000
167787
3303395
585104
2000000
65075
250000000
500000000
0
0
0
0
0
319553
2851947
85372
46523
1400125
2850000
15645528
22159446
22159446
1.98
1400125
100000000
0.0001
3232003
89177556
2611091
3395067
0
6834037
31615275
827879
-57564497
2216
38449312
0
38249485
131555
38449312
35150924
27000000
336318
3300275
762243
2000000
68272
0
0
0
0
319553
2851947
82252
46523
13500000
1.00
3.1764
18889307
60000000
15300000
7063300
115453280
921300
1250000
1000000
P5Y3M18D
14599612
-2291365
-0.39
598252
-41895
800
3555
0
-5400616
-69517
-5638377
5055
1046608
1541938
-416664
74070
5998868
-754482
1536883
209854
241316
3362141
4952260
6199
47449
26621
598000
0
1216463
Intra-Cellular Therapies, Inc.
false
Smaller Reporting Company
2014
10-Q
2014-03-31
0001567514
--12-31
Q1
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>4. Share-Based Compensation</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
The Company sponsors the Intra-Cellular Therapies, Inc. 2013 Equity
Incentive Plan (the “2013 Plan”) to provide for the
granting of stock awards, such as stock options, restricted common
stock and stock appreciation rights to employees, directors and
other individuals as determined by the Board of Directors. In
August 2013, the Company assumed in the Merger the ITI 2003 Equity
Incentive Plan , as amended (the “2003 Plan”), which
expired by its terms in July 2013. As of March 31, 2014, the
only outstanding awards under the 2003 Plan were options to
purchase 1,400,125 shares of common stock. Effective in November
2013, the Company adopted the 2013 Plan. The Company reserved
2,850,000 shares of common stock for issuance under the 2013 Plan.
In January 2014, the Company increased the number of shares of
common stock reserved for issuance under the 2013 Plan by 800,000
pursuant to the evergreen provisions of the 2013 Plan.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
Stock options granted under the 2013 Plan may be either incentive
stock options (“ISOs”) as defined by the Internal
Revenue Code, or non-qualified stock options. The Board of
Directors determines who will receive options, the vesting periods
(which are generally two to three years) and the exercise prices of
such options. Options have a maximum term of 10 years. The exercise
price of ISOs granted under the 2013 Plan must be at least equal to
the fair market value of the common stock on the date
of grant.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
Total stock-based compensation expense, related to all of the
Company’s share-based awards to employees, directors and
non-employees recognized during three months ended March 31,
2014 and 2013, was comprised of the following:</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
<tr>
<td width="79%"></td>
<td valign="bottom" width="4%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="4%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td valign="bottom" colspan="6" align="center">
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>Three Months Ended</b></p>
<p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>March 31,</b></p>
</td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Research and development</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"><b>$</b></td>
<td valign="bottom" align="right"><b>97,417</b></td>
<td valign="bottom" nowrap="nowrap"><b>  </b></td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">26,621</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
General and administrative</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"><b> </b></td>
<td valign="bottom" align="right"><b>102,337</b></td>
<td valign="bottom" nowrap="nowrap"><b>  </b></td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">47,449</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Total share-based compensation expense</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"><b>$</b></td>
<td valign="bottom" align="right"><b>199,754</b></td>
<td valign="bottom" nowrap="nowrap"><b>  </b></td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">74,070</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
The following table describes the weighted-average assumptions used
for calculating the value of options granted during the three
months ended March 31, 2014:</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
<tr>
<td width="87%"></td>
<td valign="bottom" width="4%"></td>
<td></td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>2014</b></td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Dividend yield</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom" align="center"><b>0%</b></td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Expected volatility</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom" align="center"><b>80%</b></td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Weighted-average risk-free interest rate</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom" align="center"><b>2.0%</b></td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Expected term</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom" align="center"><b>6.4 years</b></td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
Information regarding the stock options activity including
employees, directors and non-employees as of March 31, 2014,
and changes during the three-month period then ended, are
summarized as follows:</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
<tr>
<td width="69%"></td>
<td valign="bottom" width="4%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="4%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="4%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number of<br />
Shares</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-<br />
Average<br />
Exercise<br />
Price</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-<br />
Average<br />
Contractual<br />
Life</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Outstanding at December 31, 2013 (audited)</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">1,400,125</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">1.98</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">5.3 years</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
Options granted (unaudited)</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">168,000</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">17.35</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">6.4 years</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
Options exercised (unaudited)</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom" nowrap="nowrap"> </td>
<td valign="bottom" nowrap="nowrap" align="right">
—  </td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom" nowrap="nowrap">$</td>
<td valign="bottom" nowrap="nowrap" align="right">
—  </td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom" nowrap="nowrap"> </td>
<td valign="bottom" nowrap="nowrap" align="right">
—  </td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
Options canceled or expired (unaudited)</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom" nowrap="nowrap"> </td>
<td valign="bottom" nowrap="nowrap" align="right">
—  </td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom" nowrap="nowrap">$</td>
<td valign="bottom" nowrap="nowrap" align="right">
—  </td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom" nowrap="nowrap"> </td>
<td valign="bottom" nowrap="nowrap" align="right">
—  </td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Outstanding at March 31, 2014 (unaudited)</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">1,568,125</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">3.63</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">5.6 years</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
Vested or expected to vest at March 31, 2014 (unaudited)</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">1,568,125</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">3.63</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Exercisable at March 31, 2014 (unaudited)</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">1,174,640</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">1.76</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">4.4 years</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt">
 </p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Share-Based
Compensation</b></font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2">Share-based payments are
accounted for in accordance with the provisions of ASC
Topic 718, <i>Compensation—Stock Compensation</i>. The
fair value of share-based payments is estimated, on the date of
grant, using the Black-Scholes-Merton option-pricing model (the
“Black-Scholes model”). The resulting fair value is
recognized ratably over the requisite service period, which is
generally the vesting period of the option.</font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"><font style="FONT-FAMILY: Times New Roman" size="2">For all time vesting awards
granted, expense is amortized using the straight-line attribution
method. For awards that contain a performance condition, expense is
amortized using the accelerated attribution method. As share-based
compensation expense recognized in the statements of operations for
the three months ended March 31, 2014 and 2013 is based on
share-based awards ultimately expected to vest, it has been reduced
for estimated forfeitures.</font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"><font style="FONT-FAMILY: Times New Roman" size="2">ASC Topic 718 requires
forfeitures to be estimated at the time of grant and revised, if
necessary, in subsequent periods if actual forfeitures differ from
those estimates. Pre-vesting forfeitures are based on the
Company’s historical experience for the three months ended
March 31, 2014 and 2013, and have not been
material.</font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company utilizes the
Black-Scholes model for estimating fair value of its stock options
granted. Option valuation models, including the Black-Scholes
model, require the input of subjective assumptions, and changes in
the assumptions used can materially affect the grant date fair
value of an award. These assumptions include the risk-free rate of
interest, expected dividend yield, expected volatility and the
expected life of the award.</font></p>
<p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 </p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Expected volatility rates
are based on historical volatility of the common stock of
comparable publicly traded entities and other factors due to the
lack of historic information of the Company’s common stock.
The expected life of stock-based options is the period of time for
which the stock-based options are expected to be outstanding. Given
the lack of historic exercise data, the expected life is determined
using the “simplified method” which is defined as the
midpoint between the vesting date and the end of the contractual
term.</font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"><font style="FONT-FAMILY: Times New Roman" size="2">The risk-free interest
rates are based on the U.S. Treasury yield for a period consistent
with the expected term of the option in effect at the time of the
grant. The Company has not paid dividends to its stockholders since
its inception and does not plan to pay cash dividends in the
foreseeable future. Therefore, the Company has assumed an expected
dividend rate of zero.</font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"><font style="FONT-FAMILY: Times New Roman" size="2">For the quarter ended
March 31, 2013, given that there was no active market for the
Company’s common stock, the exercise price of the stock
options on the date of grant was determined and approved by the
board of directors using several factors, including progress and
milestones achieved in the Company’s business development and
performance, the price per share of its convertible preferred stock
offerings and general industry and economic trends. In establishing
the estimated fair value of the common stock, the Company
considered the guidance set forth in American Institute of
Certified Public Accountants Practice Guide, <i>Valuation of
Privately-Held-Company Equity Securities Issued as
Compensation</i>. For the quarter ended March 31, 2014, the
exercise price was determined by using the closing market price of
our common stock on the date of grant.</font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"><font style="FONT-FAMILY: Times New Roman" size="2">Under ASC Topic 718, the
cumulative amount of compensation cost recognized for instruments
classified as equity that ordinarily would result in a future tax
deduction under existing tax law shall be considered to be a
deductible difference in applying ASC Topic 740, <i>Income
Taxes</i>. The deductible temporary difference is based on the
compensation cost recognized for financial reporting purposes;
however, these provisions currently do not impact the Company, as
all the deferred tax assets have a full valuation
allowance.</font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"><font style="FONT-FAMILY: Times New Roman" size="2">Since the Company had net
operating loss carryforwards as of March 31, 2014 and 2013, no
excess tax benefits for the tax deductions related to share-based
awards were recognized in the statements of operations.</font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"><font style="FONT-FAMILY: Times New Roman" size="2">Equity instruments issued
to non-employees are accounted for under the provisions of ASC
Topic 718 and ASC Topic 505-50, <i>Equity/Equity-Based
Payments to Non-Employees</i>. Accordingly, the estimated fair
value of the equity instrument is recorded on the earlier of the
performance commitment date or the date the services required
are completed and are marked to market during the
service period.</font></p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Fair Value
Measurements</b></font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company applies the
fair value method under ASC Topic 820, <i>Fair Value Measurements
and Disclosures</i>. ASC Topic 820 defines fair value, establishes
a fair value hierarchy for assets and liabilities measured at fair
value and requires expanded disclosures about fair value
measurements. The ASC Topic 820 hierarchy ranks the quality and
reliability of inputs, or assumptions, used in the determination of
fair value and requires assets and liabilities carried at fair
value to be classified and disclosed in one of the following
categories based on the lowest level input used that is significant
to a particular fair value measurement:</font></p>
<p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px">
 </p>
<table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="5%"><font size="1"> </font></td>
<td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">•</font></td>
<td valign="top" width="1%"><font size="1"> </font></td>
<td valign="top" align="left">
<p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Level 1—Fair value is determined by using unadjusted
quoted prices that are available in active markets for identical
assets and liabilities.</font></p>
</td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px">
 </p>
<table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="5%"><font size="1"> </font></td>
<td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">•</font></td>
<td valign="top" width="1%"><font size="1"> </font></td>
<td valign="top" align="left">
<p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Level 2—Fair value is determined by using inputs
other than Level 1 quoted prices that are directly or indirectly
observable. Inputs can include quoted prices for similar assets and
liabilities in active markets or quoted prices for identical assets
and liabilities in inactive markets. Related inputs can also
include those used in valuation or other pricing models, such as
interest rates and yield curves that can be corroborated by
observable market data.</font></p>
</td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px">
 </p>
<table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="5%"><font size="1"> </font></td>
<td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">•</font></td>
<td valign="top" width="1%"><font size="1"> </font></td>
<td valign="top" align="left">
<p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Level 3—Fair value is determined by inputs that are
unobservable and not corroborated by market data. Use of these
inputs involves significant and subjective judgments to be made by
a reporting entity – e.g., determining an appropriate
adjustment to a discount factor for illiquidity associated with a
given security.</font></p>
</td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company evaluates
financial assets and liabilities subject to fair value measurements
on a recurring basis to determine the appropriate level at which to
classify them each reporting period. This determination requires
the Company to make subjective judgments as to the significance of
inputs used in determining fair value and where such inputs lie
within the ASC Topic 820 hierarchy.</font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company has no assets
or liabilities that were measured using quoted prices for similar
assets and liabilities or significant unobservable inputs (Level 2
and Level 3 assets and liabilities, respectively) as of
March 31, 2014 and December 31, 2013. The carrying value
of cash held in money market funds of approximately $27.2 million
as of March 31, 2014 and approximately $27.0 million as of
December 31, 2013, is included in cash and cash equivalents
and approximates market value based on quoted market price or Level
1 inputs.</font></p>
</div>
0.020
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>Revenue Recognition</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
Revenue is recognized when all terms and conditions of the
agreements have been met, including persuasive evidence of an
arrangement, delivery has occurred or services have been rendered,
price is fixed or determinable and collectability is reasonably
assured. The Company is reimbursed for certain costs incurred on
specified research projects under the terms and conditions of
grants, collaboration agreements, and awards. The Company records
the amount of reimbursement as revenues on a gross basis in
accordance with ASC Topic 605-45, <i>Revenue Recognition/Principal
Agent Considerations</i>. The Company is the primary obligor with
respect to purchasing goods and services from third-party
suppliers, is obligated to compensate the service provider for the
work performed, and has discretion in selecting the supplier.
Provisions for estimated losses on research grant projects and any
other contracts are made in the period such losses are
determined.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
Effective January 1, 2011, the Company adopted a new
accounting standard that amends the guidance on the accounting for
arrangements involving the delivery of more than one element.
Pursuant to the new standard, each required deliverable is
evaluated to determine whether it qualifies as a separate unit of
accounting. For ITI, this determination is generally based on
whether the deliverable has “stand-alone value” to the
customer. The Company adopted this new accounting standard on a
prospective basis for all Multiple-Deliverable Revenue Arrangements
(“MDRAs”) entered into on or after January 1,
2011, and for any MDRAs that were entered into prior to
January 1, 2011, but materially modified on or after that
date.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
For MDRAs entered into prior to January 1, 2011 (pre-2011
arrangements) and not materially modified thereafter, the Company
continues to apply its prior accounting policy with respect to such
arrangements. Under this policy, in general, revenue from
non-refundable, up-front fees related to intellectual property
rights/licenses, where the Company has continuing involvement and
where standalone value could not be determined under the previous
guidance, is recognized ratably over the estimated period of
ongoing involvement. In general, the consideration with respect to
the other deliverables is recognized when the goods or services are
delivered.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
The adoption of this accounting standard did not have a material
impact on the Company’s results of operations for the
quarters ended March 31, 2014 and 2013, or on the
Company’s financial positions as of March 31, 2014 and
December 31, 2013.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
The Company recognizes milestone revenue contingent upon the
achievement of a substantive milestone in its entirety in the
period the milestone is achieved in accordance with ASC
Topic 605-28 milestone method. Substantive milestone payments
are recognized upon achievement of the milestone only if all of the
following conditions are met:</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="5%"> </td>
<td valign="top" width="2%" align="left">•</td>
<td valign="top" width="1%"> </td>
<td valign="top" align="left">The milestone payments are
non-refundable;</td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="5%"> </td>
<td valign="top" width="2%" align="left">•</td>
<td valign="top" width="1%"> </td>
<td valign="top" align="left">Achievement of the milestone involves
a degree of risk and was not reasonably assured at the inception of
the arrangement;</td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="5%"> </td>
<td valign="top" width="2%" align="left">•</td>
<td valign="top" width="1%"> </td>
<td valign="top" align="left">Substantive effort on our part is
involved in achieving the milestone;</td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="5%"> </td>
<td valign="top" width="2%" align="left">•</td>
<td valign="top" width="1%"> </td>
<td valign="top" align="left">The amount of the milestone payment
is reasonable in relation to the effort expended or the risk
associated with achievement of the milestone; and</td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="5%"> </td>
<td valign="top" width="2%" align="left">•</td>
<td valign="top" width="1%"> </td>
<td valign="top" align="left">A reasonable amount of time passes
between the up-front license payment and the first milestone
payment, as well as between each subsequent milestone payment.</td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
Determination as to whether a payment meets the aforementioned
conditions involves management’s judgment. If any of these
conditions are not met, the resulting payment would not be
considered a substantive milestone, and therefore, the resulting
payment would be considered part of the consideration for the
single unit of accounting and be recognized as revenue in
accordance with the revenue models described above. In addition,
the determination that one such payment was not a substantive
milestone could prevent the Company from concluding that subsequent
milestone payments were substantive milestones and, as a result,
any additional milestone payments could also be considered part of
the consideration for the single unit of accounting and would be
recognized as revenue as such performance obligations are performed
under either the proportional performance or straight-line methods,
as applicable.</p>
<p> </p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
<b>5. Collaborations and License Agreements</b></p>
<!-- xbrl,body -->
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
<b>The Bristol-Myers Squibb License Agreement</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
On May 31, 2005 the Company (through its wholly owned
operating subsidiary, ITI) entered into a world-wide, exclusive
License Agreement with Bristol-Myers Squibb Company (BMS), pursuant
to which the Company holds a license to certain patents and
know-how of BMS relating to ITI-007 and other specified compounds.
The agreement was amended on November 3, 2010. The licensed
rights are exclusive, except BMS retains rights in specified
compounds in the fields of obesity, diabetes, metabolic syndrome
and cardiovascular disease. However, BMS has no right to use,
develop or commercialize ITI-007 and other specified compounds in
any field of use. The Company has the right to grant sublicenses of
the rights conveyed by BMS. The Company is obliged under the
license to use commercially reasonable efforts to develop and
commercialize the licensed technology. The Company is also
prohibited from engaging in the clinical development or
commercialization of specified competitive compounds.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
Under the agreement, the Company made an upfront payment of $1.0
million to BMS and a milestone payment of $1.25 million in December
2013, and may be obliged to make other milestone payments for each
licensed product of up to an aggregate of approximately $13.5
million. The Company is also obliged to make tiered single digit
percentage royalty payments on sales of licensed products. The
Company is obliged to pay to BMS a percentage of non-royalty
payments made in consideration of any sublicense.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
The agreement extends, and royalties are payable, on a
country-by-country and product-by-product basis, through the later
of ten years after first commercial sale of a licensed product in
such country, expiration of the last licensed patent covering a
licensed product, its method of manufacture or use, or the
expiration of other government grants providing market exclusivity,
subject to certain rights of the parties to terminate the agreement
on the occurrence of certain events. On termination of the
agreement, the Company may be obliged to convey to BMS rights in
developments relating to a licensed compound or licensed product,
including regulatory filings, research results and other
intellectual property rights.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>The Takeda License and Collaboration Agreement</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
On February 25, 2011, the Company (through its wholly owned
operating subsidiary, ITI) entered into a license and collaboration
agreement with Takeda Pharmaceutical Company Limited
(“Takeda”) under which the Company agreed to
collaborate to research, develop and commercialize its proprietary
compound ITI-214 and other selected compounds that selectively
inhibit phosphodiesterase type 1 (“PDE1”) for use in
the prevention and treatment of human diseases. As part of the
agreement, the Company assigned to Takeda certain patents owned by
the Company that claim ITI-214 and granted Takeda an exclusive
license to develop and commercialize compounds identified in the
conduct of the research program that satisfy specified criteria.
However, the Company has retained rights to all compounds that do
not meet the specified criteria and the Company continues to
develop PDE1 inhibitors outside the scope of the agreement.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
Under the terms of the agreement, the Company has conducted a
research program with an initial term of three years to identify
and characterize compounds that meet certain specified criteria
sufficient for further development by Takeda. This research program
ended in February 2014. The Company was responsible for the
Company’s expenses incurred in the conduct of certain
research activities specified in the research plan. Takeda agreed
to reimburse the Company for expenses the Company incurred in
conducting additional research activities.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
Takeda is obliged to use commercially reasonable efforts to develop
and commercialize licensed compounds at its expense, and has agreed
to reimburse the Company for the costs and expenses of development
activities the Company may perform. The Company formed a joint
steering committee with Takeda to coordinate and oversee activities
on which the Company and Takeda collaborate under the agreement.
The Company has the option to co-promote any licensed product in
the United States by assuming responsibility for a certain
percentage of the detailing activity with respect to that
product.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
We fulfilled our responsibility under the agreement to supply
Takeda with ITI-214 for nonclinical activities and Phase 1 clinical
trials at our expense. Takeda is responsible, at its expense, for
the manufacture and supply of compounds that it develops and
commercializes under the agreement for all other activities.</p>
<p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 </p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
Upon execution of the agreement, Takeda made a nonrefundable
payment to the Company. The Company is eligible to receive payments
of approximately $500 million in the aggregate upon achievement of
certain development milestones and up to an additional $250 million
in the aggregate upon achievement of certain sales-based
milestones, along with tiered royalty payments ranging from the
high single digits to the low teens in percent based on net sales
by Takeda.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
The agreement extends, on a country-by-country and
product-by-product basis, through the later of expiration of the
last licensed patent covering a licensed product, its method of
manufacture or use, the expiration of other government grants
providing market exclusivity or 10 years after first commercial
sale of a licensed product in such country, subject to rights of
the parties to sooner terminate the agreement on certain events and
the right of Takeda to unilaterally terminate the agreement upon a
specified number of days’ prior notice. Upon the termination
of the agreement, Takeda is obliged to assign to the Company the
patents covering ITI-214 assigned to Takeda upon the execution of
the agreement, to grant the Company a license to develop and
commercialize licensed compounds developed by Takeda and to
transfer to the Company certain materials, information and
regulatory materials reasonably necessary for the Company to
continue the development and commercialization of those
compounds.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
The Company evaluates all deliverables within an arrangement to
determine whether or not they provide value on a stand-alone basis.
The Company identified two deliverables in the arrangement,
(1) a license to the Company’s intellectual property,
and (2) research and development services (“R&D
services”). Based on this evaluation, the deliverables were
separated into units of accounting. The arrangement consideration
that is fixed or determinable at the inception of the arrangement
was allocated to the separate units of accounting based on their
relative selling prices. The Company may exercise significant
judgment in determining whether a deliverable is a separate unit of
accounting, as well as in estimating the selling prices of such
unit of accounting.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
To determine the selling price of a separate deliverable, the
Company uses the hierarchy as prescribed in ASC Topic 605-25
<i>Revenue Recognition</i> based on vendor-specific objective
evidence (“VSOE”), third-party evidence
(“TPE”) or best estimate of selling price
(“BESP”). VSOE is based on the price charged when the
element is sold separately and is the price actually charged for
that deliverable. TPE is determined based on third-party evidence
for a similar deliverable when sold separately and BESP is the
price at which the Company would transact a sale if the elements of
collaboration and license arrangements were sold on a stand-alone
basis. The Company was not able to establish VSOE or TPE for the
deliverables within collaboration and license arrangements, as the
Company does not have a history of entering into such arrangements
or selling the individual deliverables within such arrangements
separately. In addition, there may be significant differentiation
in these arrangements, which indicates that comparable third-party
pricing may not be available. The Company determined that the
selling price for the deliverables within collaboration and license
arrangements should be determined using BESP. The process for
determining BESP involved significant judgment on our part and
included consideration of multiple factors such as prices offered
by third parties, estimated direct expenses and other costs, and
available data. The Company was able to determine the BESP for the
license and R&D services, and thus, allocated the consideration
in this arrangement based on relative selling price of each
deliverable. The revenue allocated to the license was recognized
upon the execution of the agreement as Takeda obtained the right to
use the license upon execution of the agreement. The revenue for
R&D services is being recognized over the estimated service
period of 3 years.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
During the three months ended March 31, 2014 and 2013, the
Company recognized revenue of $168,000 and $598,000 under this
agreement, respectively. At March 31, 2014 and 2013, $0 and
$1.25 million of revenue was deferred under this
agreement.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>Other License Agreement</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
In May 2002, ITI entered into a license agreement (the
“License”) and research agreement with a university.
Under the provisions of the License, ITI is entitled to use this
organization’s patented technology and other intellectual
property relating to diagnosis and treatment of central nervous
system disorders.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
The License expires upon expiration of the patent rights or 15
years subsequent to the first sale of products developed through
this License. ITI is required to make future milestone payments for
initiation of clinical trials and approval of a New Drug
Application (“NDA”). Should ITI commercialize the
technology related to this License, ITI would be required to make
royalty payments, and would also be required to pay fees under any
sublicense agreements with third parties.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
In connection with the License, ITI issued 400,000 shares of common
stock to the organization. Upon issuance of the shares, ITI
recorded the estimated fair value of the shares issued,
approximately $120,000, as research and development expense.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
In addition, ITI is required to use at least $1.0 million
annually of its resources for the development and commercialization
of the technology until ITI submits an NDA. ITI met its spending
requirements in 2013. There were no other payments made or required
for the three months ended March 31, 2014 and 2013.</p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
Information regarding the stock options activity including
employees, directors and non-employees as of March 31, 2014,
and changes during the three-month period then ended, are
summarized as follows:</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
<tr>
<td width="69%"></td>
<td valign="bottom" width="4%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="4%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="4%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number of<br />
Shares</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-<br />
Average<br />
Exercise<br />
Price</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-<br />
Average<br />
Contractual<br />
Life</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Outstanding at December 31, 2013 (audited)</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">1,400,125</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">1.98</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">5.3 years</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
Options granted (unaudited)</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">168,000</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">17.35</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">6.4 years</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
Options exercised (unaudited)</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom" nowrap="nowrap"> </td>
<td valign="bottom" nowrap="nowrap" align="right">
—  </td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom" nowrap="nowrap">$</td>
<td valign="bottom" nowrap="nowrap" align="right">
—  </td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom" nowrap="nowrap"> </td>
<td valign="bottom" nowrap="nowrap" align="right">
—  </td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
Options canceled or expired (unaudited)</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom" nowrap="nowrap"> </td>
<td valign="bottom" nowrap="nowrap" align="right">
—  </td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom" nowrap="nowrap">$</td>
<td valign="bottom" nowrap="nowrap" align="right">
—  </td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom" nowrap="nowrap"> </td>
<td valign="bottom" nowrap="nowrap" align="right">
—  </td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Outstanding at March 31, 2014 (unaudited)</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">1,568,125</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">3.63</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">5.6 years</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
Vested or expected to vest at March 31, 2014 (unaudited)</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">1,568,125</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">3.63</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Exercisable at March 31, 2014 (unaudited)</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">1,174,640</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">1.76</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">4.4 years</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt">
 </p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Comprehensive Income
(Loss)</b></font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2">ASC Topic 220-10,
<i>Reporting Comprehensive Income</i>, requires the presentation of
the comprehensive income or loss and its components as part of the
financial statements if comprehensive income (loss) differs from
net income (loss). For the three months ended March 31, 2014
and 2013, the Company’s net loss equals comprehensive
loss.</font></p>
</div>
0.80
<div>
<p style="margin-top:6px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">Property and equipment
consist of the following:</font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px">
 </p>
<table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center">
<tr>
<td width="72%"></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>March 31,</b></font><br />
<font style="font-family:Times New Roman" size="1"><b>2014</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>December 31,</b></font><br />
<font style="font-family:Times New Roman" size="1"><b>2013</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr>
<td height="8"></td>
<td height="8" colspan="4"></td>
<td height="8" colspan="4"></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Computer
equipment</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"><b>$</b></font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2"><b>85,372</b></font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2"><b>  </b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">82,252</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Furniture and
fixtures</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"><b> </b></font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2"><b>46,523</b></font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2"><b>  </b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">46,523</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Scientific
equipment</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"><b> </b></font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2"><b>2,851,947</b></font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2"><b>  </b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">2,851,947</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Leasehold
improvements</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"><b> </b></font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2"><b>319,553</b></font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2"><b>  </b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">319,553</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top"></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"><b> </b></font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2"><b>3,303,395</b></font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2"><b>  </b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">3,300,275</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Less accumulated
depreciation</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"><b> </b></font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2"><b>(3,238,320</b></font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2"><b>) </b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">(3,232,003</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">) </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top"></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"><b>$</b></font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2"><b>65,075</b></font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2"><b>  </b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">68,272</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
</tr>
</table>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
<font style="FONT-FAMILY: Times New Roman" size="2">The following common stock equivalents were excluded in
the calculation of diluted loss per share because their effect
would be anti-dilutive as applied to the loss from operations as of
the three months ended March 31, 2014 and 2013:</font></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
<font style="FONT-FAMILY: Times New Roman" size="2"> </font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"></p>
<table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
<tr>
<td width="78%"></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td valign="bottom" colspan="6" align="center">
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>Three Months Ended</b></p>
<p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>March 31,</b></p>
</td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Stock options</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">941,279</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">1,216,463</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
</table>
</div>
<div>
<p style="margin-top:0px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2"><b>3. Property and
Equipment</b></font></p>
<p style="margin-top:6px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">Property and equipment
consist of the following:</font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px">
 </p>
<table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center">
<tr>
<td width="72%"></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>March 31,</b></font><br />
<font style="font-family:Times New Roman" size="1"><b>2014</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>December 31,</b></font><br />
<font style="font-family:Times New Roman" size="1"><b>2013</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr>
<td height="8"></td>
<td height="8" colspan="4"></td>
<td height="8" colspan="4"></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Computer
equipment</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"><b>$</b></font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2"><b>85,372</b></font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2"><b>  </b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">82,252</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Furniture and
fixtures</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"><b> </b></font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2"><b>46,523</b></font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2"><b>  </b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">46,523</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Scientific
equipment</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"><b> </b></font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2"><b>2,851,947</b></font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2"><b>  </b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">2,851,947</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Leasehold
improvements</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"><b> </b></font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2"><b>319,553</b></font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2"><b>  </b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">319,553</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top"></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"><b> </b></font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2"><b>3,303,395</b></font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2"><b>  </b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">3,300,275</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Less accumulated
depreciation</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"><b> </b></font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2"><b>(3,238,320</b></font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2"><b>) </b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">(3,232,003</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">) </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top"></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"><b>$</b></font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2"><b>65,075</b></font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2"><b>  </b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">68,272</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
</tr>
</table>
<p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">Depreciation expense for the
three months ended March 31, 2014 and 2013 was $6,317 and
$6,199 respectively.</font></p>
</div>
P5Y7M6D
168000
P6Y4M24D
<div>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Accounts
Receivable</b></font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2">Accounts receivable that
management has the intent and ability to collect are reported in
the balance sheets at outstanding amounts, less an allowance for
doubtful accounts. The Company writes off uncollectible receivables
when the likelihood of collection is remote.</font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company evaluates the
collectability of accounts receivable on a regular basis. The
allowance, if any, is based upon various factors including the
financial condition and payment history of customers, an overall
review of collections experience on other accounts and economic
factors or events expected to affect future collections experience.
No allowance was recorded as of March 31, 2014 and
December 31, 2013, as the Company has a history of collecting
on all its accounts, including government agencies and
collaborations funding its research.</font></p>
</div>
P10Y
26475907
17.35
-6982837
<div>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Property and
Equipment</b></font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2">Property and equipment is
stated at cost and depreciated on a straight-line basis over
estimated useful lives ranging from three to five years. Leasehold
improvements are amortized using the straight-line method over the
shorter of the estimated useful life of the assets or the term of
the related lease. Expenditures for maintenance and repairs are
charged to operations as incurred.</font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"><font style="FONT-FAMILY: Times New Roman" size="2">When indicators of possible
impairment are identified, the Company evaluates the recoverability
of the carrying value of its long-lived assets based on the
criteria established in ASC Topic 360, <i>Property, Plant and
Equipment</i>. The Company considers historical performance and
anticipated future results in its evaluation of potential
impairment. The Company evaluates the carrying value of those
assets in relation to the operating performance of the business and
undiscounted cash flows expected to result from the use of those
assets. Impairment losses are recognized when carrying value
exceeds the undiscounted cash flows, in which case management must
determine the fair value of the underlying asset. No such
impairment losses have been recognized to date.</font></p>
</div>
0.00
<div>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Cash and Cash
Equivalents</b></font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company considers all
highly liquid investments with a maturity of three months or less
from the date of purchase to be cash equivalents. Cash and cash
equivalents consist of certificates of deposit with commercial
banks and financial institutions. Certificates of deposit with a
maturity date of more than three months are classified separately
on the balance sheet. Their carrying values approximate the fair
market value.</font></p>
</div>
-0.17
<div>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Research and
Development</b></font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2">Except for payments made in
advance of services, the Company expenses its research and
development costs as incurred. For payments made in advance, the
Company recognizes research and development expense as the services
are rendered. Research and development costs primarily consist of
salaries and related expenses for personnel and resources and the
costs of clinical trials. Other research and development expenses
include pre-clinical analytical testing, outside services,
providers, materials and consulting fees.</font></p>
</div>
P4Y4M24D
<div>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Concentration of Credit
Risk</b></font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2">Cash equivalents are held
with major financial institutions in the United States.
Certificates of deposit held with banks may exceed the amount of
insurance provided on such deposits. Generally, these deposits may
be redeemed upon demand and, therefore, bear minimal
risk.</font></p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>2. Summary of Significant Accounting Policies</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
<b>Use of Estimates</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
The preparation of financial statements in conformity with
generally accepted accounting principles requires management to
make estimates and assumptions that affect the amounts reported in
the financial statements and accompanying notes. Although actual
results could differ from those estimates, management does not
believe that such differences would be material.</p>
<p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 </p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
<b>Cash and Cash Equivalents</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
The Company considers all highly liquid investments with a maturity
of three months or less from the date of purchase to be cash
equivalents. Cash and cash equivalents consist of certificates of
deposit with commercial banks and financial institutions.
Certificates of deposit with a maturity date of more than three
months are classified separately on the balance sheet. Their
carrying values approximate the fair market value.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>Fair Value Measurements</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
The Company applies the fair value method under ASC Topic 820,
<i>Fair Value Measurements and Disclosures</i>. ASC Topic 820
defines fair value, establishes a fair value hierarchy for assets
and liabilities measured at fair value and requires expanded
disclosures about fair value measurements. The ASC Topic 820
hierarchy ranks the quality and reliability of inputs, or
assumptions, used in the determination of fair value and requires
assets and liabilities carried at fair value to be classified and
disclosed in one of the following categories based on the lowest
level input used that is significant to a particular fair value
measurement:</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="5%"> </td>
<td valign="top" width="2%" align="left">•</td>
<td valign="top" width="1%"> </td>
<td valign="top" align="left">Level 1—Fair value is
determined by using unadjusted quoted prices that are available in
active markets for identical assets and liabilities.</td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="5%"> </td>
<td valign="top" width="2%" align="left">•</td>
<td valign="top" width="1%"> </td>
<td valign="top" align="left">Level 2—Fair value is
determined by using inputs other than Level 1 quoted prices that
are directly or indirectly observable. Inputs can include quoted
prices for similar assets and liabilities in active markets or
quoted prices for identical assets and liabilities in inactive
markets. Related inputs can also include those used in valuation or
other pricing models, such as interest rates and yield curves that
can be corroborated by observable market data.</td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="5%"> </td>
<td valign="top" width="2%" align="left">•</td>
<td valign="top" width="1%"> </td>
<td valign="top" align="left">Level 3—Fair value is
determined by inputs that are unobservable and not corroborated by
market data. Use of these inputs involves significant and
subjective judgments to be made by a reporting entity –
e.g., determining an appropriate adjustment to a discount factor
for illiquidity associated with a given security.</td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
The Company evaluates financial assets and liabilities subject to
fair value measurements on a recurring basis to determine the
appropriate level at which to classify them each reporting period.
This determination requires the Company to make subjective
judgments as to the significance of inputs used in determining fair
value and where such inputs lie within the ASC Topic 820
hierarchy.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
The Company has no assets or liabilities that were measured using
quoted prices for similar assets and liabilities or significant
unobservable inputs (Level 2 and Level 3 assets and liabilities,
respectively) as of March 31, 2014 and December 31, 2013.
The carrying value of cash held in money market funds of
approximately $27.2 million as of March 31, 2014 and
approximately $27.0 million as of December 31, 2013, is
included in cash and cash equivalents and approximates market value
based on quoted market price or Level 1 inputs.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>Financial Instruments</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
The Company considers the recorded costs of its financial assets
and liabilities, which consist of cash equivalents, accounts
receivable, accounts payable and accrued liabilities, to
approximate their fair value because of their relatively short
maturities at March 31, 2014 and December 31, 2013.
Management believes that the risks associated with its financial
instruments are minimal as the counterparties are various
corporations, financial institutions and government agencies of
high credit standing.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>Concentration of Credit Risk</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
Cash equivalents are held with major financial institutions in the
United States. Certificates of deposit held with banks may exceed
the amount of insurance provided on such deposits. Generally, these
deposits may be redeemed upon demand and, therefore, bear minimal
risk.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>Accounts Receivable</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
Accounts receivable that management has the intent and ability to
collect are reported in the balance sheets at outstanding amounts,
less an allowance for doubtful accounts. The Company writes off
uncollectible receivables when the likelihood of collection is
remote.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
The Company evaluates the collectability of accounts receivable on
a regular basis. The allowance, if any, is based upon various
factors including the financial condition and payment history of
customers, an overall review of collections experience on other
accounts and economic factors or events expected to affect future
collections experience. No allowance was recorded as of
March 31, 2014 and December 31, 2013, as the Company has
a history of collecting on all its accounts, including government
agencies and collaborations funding its research.</p>
<p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 </p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
<b>Property and Equipment</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
Property and equipment is stated at cost and depreciated on a
straight-line basis over estimated useful lives ranging from three
to five years. Leasehold improvements are amortized using the
straight-line method over the shorter of the estimated useful life
of the assets or the term of the related lease. Expenditures for
maintenance and repairs are charged to operations as incurred.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
When indicators of possible impairment are identified, the Company
evaluates the recoverability of the carrying value of its
long-lived assets based on the criteria established in ASC
Topic 360, <i>Property, Plant and Equipment</i>. The Company
considers historical performance and anticipated future results in
its evaluation of potential impairment. The Company evaluates the
carrying value of those assets in relation to the operating
performance of the business and undiscounted cash flows expected to
result from the use of those assets. Impairment losses are
recognized when carrying value exceeds the undiscounted cash flows,
in which case management must determine the fair value of the
underlying asset. No such impairment losses have been recognized to
date.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>Revenue Recognition</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
Revenue is recognized when all terms and conditions of the
agreements have been met, including persuasive evidence of an
arrangement, delivery has occurred or services have been rendered,
price is fixed or determinable and collectability is reasonably
assured. The Company is reimbursed for certain costs incurred on
specified research projects under the terms and conditions of
grants, collaboration agreements, and awards. The Company records
the amount of reimbursement as revenues on a gross basis in
accordance with ASC Topic 605-45, <i>Revenue Recognition/Principal
Agent Considerations</i>. The Company is the primary obligor with
respect to purchasing goods and services from third-party
suppliers, is obligated to compensate the service provider for the
work performed, and has discretion in selecting the supplier.
Provisions for estimated losses on research grant projects and any
other contracts are made in the period such losses are
determined.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
Effective January 1, 2011, the Company adopted a new
accounting standard that amends the guidance on the accounting for
arrangements involving the delivery of more than one element.
Pursuant to the new standard, each required deliverable is
evaluated to determine whether it qualifies as a separate unit of
accounting. For ITI, this determination is generally based on
whether the deliverable has “stand-alone value” to the
customer. The Company adopted this new accounting standard on a
prospective basis for all Multiple-Deliverable Revenue Arrangements
(“MDRAs”) entered into on or after January 1,
2011, and for any MDRAs that were entered into prior to
January 1, 2011, but materially modified on or after that
date.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
For MDRAs entered into prior to January 1, 2011 (pre-2011
arrangements) and not materially modified thereafter, the Company
continues to apply its prior accounting policy with respect to such
arrangements. Under this policy, in general, revenue from
non-refundable, up-front fees related to intellectual property
rights/licenses, where the Company has continuing involvement and
where standalone value could not be determined under the previous
guidance, is recognized ratably over the estimated period of
ongoing involvement. In general, the consideration with respect to
the other deliverables is recognized when the goods or services are
delivered.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
The adoption of this accounting standard did not have a material
impact on the Company’s results of operations for the
quarters ended March 31, 2014 and 2013, or on the
Company’s financial positions as of March 31, 2014 and
December 31, 2013.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
The Company recognizes milestone revenue contingent upon the
achievement of a substantive milestone in its entirety in the
period the milestone is achieved in accordance with ASC
Topic 605-28 milestone method. Substantive milestone payments
are recognized upon achievement of the milestone only if all of the
following conditions are met:</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="5%"> </td>
<td valign="top" width="2%" align="left">•</td>
<td valign="top" width="1%"> </td>
<td valign="top" align="left">The milestone payments are
non-refundable;</td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="5%"> </td>
<td valign="top" width="2%" align="left">•</td>
<td valign="top" width="1%"> </td>
<td valign="top" align="left">Achievement of the milestone involves
a degree of risk and was not reasonably assured at the inception of
the arrangement;</td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="5%"> </td>
<td valign="top" width="2%" align="left">•</td>
<td valign="top" width="1%"> </td>
<td valign="top" align="left">Substantive effort on our part is
involved in achieving the milestone;</td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="5%"> </td>
<td valign="top" width="2%" align="left">•</td>
<td valign="top" width="1%"> </td>
<td valign="top" align="left">The amount of the milestone payment
is reasonable in relation to the effort expended or the risk
associated with achievement of the milestone; and</td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="5%"> </td>
<td valign="top" width="2%" align="left">•</td>
<td valign="top" width="1%"> </td>
<td valign="top" align="left">A reasonable amount of time passes
between the up-front license payment and the first milestone
payment, as well as between each subsequent milestone payment.</td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
Determination as to whether a payment meets the aforementioned
conditions involves management’s judgment. If any of these
conditions are not met, the resulting payment would not be
considered a substantive milestone, and therefore, the resulting
payment would be considered part of the consideration for the
single unit of accounting and be recognized as revenue in
accordance with the revenue models described above. In addition,
the determination that one such payment was not a substantive
milestone could prevent the Company from concluding that subsequent
milestone payments were substantive milestones and, as a result,
any additional milestone payments could also be considered part of
the consideration for the single unit of accounting and would be
recognized as revenue as such performance obligations are performed
under either the proportional performance or straight-line methods,
as applicable.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>Deferred Revenue</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
Cash received as prepayment on future services is deferred and
recognized as revenue as the services are performed. The Company
must remit interest on any deferred revenue related to a
governmental agency. As of March 31, 2014 and
December 31, 2013, no interest was due as the Company did not
have any deferred revenue from a government agency.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>Research and Development</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
Except for payments made in advance of services, the Company
expenses its research and development costs as incurred. For
payments made in advance, the Company recognizes research and
development expense as the services are rendered. Research and
development costs primarily consist of salaries and related
expenses for personnel and resources and the costs of clinical
trials. Other research and development expenses include
pre-clinical analytical testing, outside services, providers,
materials and consulting fees.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>Income Taxes</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
Income taxes are accounted for using the liability method. Deferred
tax assets and liabilities are recognized for the future tax
consequences attributable to differences between the financial
statement carrying amounts of existing assets and liabilities and
its respective tax bases. Deferred tax assets and liabilities are
measured using enacted tax rates expected to apply to taxable
income in the year in which those temporary differences are
expected to be recovered or settled.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
The effect on deferred tax assets and liabilities of a change in
tax rates is recognized in income in the period that includes the
enactment date. Valuation allowances are established when necessary
to reduce net deferred tax assets to the amount expected to be
realized. Income tax expense is the tax payable for the period and
the change during the period in deferred tax assets and
liabilities.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
The Company accounts for uncertain tax positions pursuant to ASC
Topic 740 (previously included in FASB Interpretation No. 48,
<i>Accounting for Uncertainty in Income Taxes–an
Interpretation of FASB Statement No. 109)</i>. Financial
statement recognition of a tax position taken or expected to be
taken in a tax return is determined based on a more-likely-than-not
threshold of that position being sustained. If the tax position
meets this threshold, the benefit to be recognized is measured as
the tax benefit having the highest likelihood of being realized
upon ultimate settlement with the taxing authority. The Company
recognizes interest accrued related to unrecognized tax benefits
and penalties in the provision for income taxes.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>Comprehensive Income (Loss)</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
ASC Topic 220-10, <i>Reporting Comprehensive Income</i>, requires
the presentation of the comprehensive income or loss and its
components as part of the financial statements if comprehensive
income (loss) differs from net income (loss). For the three months
ended March 31, 2014 and 2013, the Company’s net loss
equals comprehensive loss.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>Share-Based Compensation</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
Share-based payments are accounted for in accordance with the
provisions of ASC Topic 718, <i>Compensation—Stock
Compensation</i>. The fair value of share-based payments is
estimated, on the date of grant, using the Black-Scholes-Merton
option-pricing model (the “Black-Scholes model”). The
resulting fair value is recognized ratably over the requisite
service period, which is generally the vesting period of the
option.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
For all time vesting awards granted, expense is amortized using the
straight-line attribution method. For awards that contain a
performance condition, expense is amortized using the accelerated
attribution method. As share-based compensation expense recognized
in the statements of operations for the three months ended
March 31, 2014 and 2013 is based on share-based awards
ultimately expected to vest, it has been reduced for estimated
forfeitures.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
ASC Topic 718 requires forfeitures to be estimated at the time of
grant and revised, if necessary, in subsequent periods if actual
forfeitures differ from those estimates. Pre-vesting forfeitures
are based on the Company’s historical experience for the
three months ended March 31, 2014 and 2013, and have not been
material.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
The Company utilizes the Black-Scholes model for estimating fair
value of its stock options granted. Option valuation models,
including the Black-Scholes model, require the input of subjective
assumptions, and changes in the assumptions used can materially
affect the grant date fair value of an award. These assumptions
include the risk-free rate of interest, expected dividend yield,
expected volatility and the expected life of the award.</p>
<p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 </p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
Expected volatility rates are based on historical volatility of the
common stock of comparable publicly traded entities and other
factors due to the lack of historic information of the
Company’s common stock. The expected life of stock-based
options is the period of time for which the stock-based options are
expected to be outstanding. Given the lack of historic exercise
data, the expected life is determined using the “simplified
method” which is defined as the midpoint between the vesting
date and the end of the contractual term.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
The risk-free interest rates are based on the U.S. Treasury yield
for a period consistent with the expected term of the option in
effect at the time of the grant. The Company has not paid dividends
to its stockholders since its inception and does not plan to pay
cash dividends in the foreseeable future. Therefore, the Company
has assumed an expected dividend rate of zero.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
For the quarter ended March 31, 2013, given that there was no
active market for the Company’s common stock, the exercise
price of the stock options on the date of grant was determined and
approved by the board of directors using several factors, including
progress and milestones achieved in the Company’s business
development and performance, the price per share of its convertible
preferred stock offerings and general industry and economic trends.
In establishing the estimated fair value of the common stock, the
Company considered the guidance set forth in American Institute of
Certified Public Accountants Practice Guide, <i>Valuation of
Privately-Held-Company Equity Securities Issued as
Compensation</i>. For the quarter ended March 31, 2014, the
exercise price was determined by using the closing market price of
our common stock on the date of grant.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
Under ASC Topic 718, the cumulative amount of compensation cost
recognized for instruments classified as equity that ordinarily
would result in a future tax deduction under existing tax law shall
be considered to be a deductible difference in applying ASC
Topic 740, <i>Income Taxes</i>. The deductible temporary
difference is based on the compensation cost recognized for
financial reporting purposes; however, these provisions currently
do not impact the Company, as all the deferred tax assets have a
full valuation allowance.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
Since the Company had net operating loss carryforwards as of
March 31, 2014 and 2013, no excess tax benefits for the tax
deductions related to share-based awards were recognized in the
statements of operations.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
Equity instruments issued to non-employees are accounted for under
the provisions of ASC Topic 718 and ASC Topic 505-50,
<i>Equity/Equity-Based Payments to Non-Employees</i>. Accordingly,
the estimated fair value of the equity instrument is recorded on
the earlier of the performance commitment date or the date the
services required are completed and are marked to market during the
service period.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>Loss Per Share</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
Basic net loss per common share is determined by dividing the net
loss by the weighted-average number of common shares outstanding
during the period, without consideration of common stock
equivalents. Diluted net loss per share is computed by dividing the
net loss by the weighted-average number of common stock equivalents
outstanding for the period. The treasury stock method is used to
determine the dilutive effect of the Company’s stock option
grants.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
The following common stock equivalents were excluded in the
calculation of diluted loss per share because their effect would be
anti-dilutive as applied to the loss from operations as of the
three months ended March 31, 2014 and 2013:</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
<tr>
<td width="78%"></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td valign="bottom" colspan="6" align="center">
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>Three Months Ended</b></p>
<p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>March 31,</b></p>
</td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Stock options</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">941,279</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">1,216,463</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
</table>
</div>
<div>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"><font style="FONT-FAMILY: Times New Roman" size="2">Total stock-based
compensation expense, related to all of the Company’s
share-based awards to employees, directors and non-employees
recognized during three months ended March 31, 2014 and 2013,
was comprised of the following:</font></p>
<p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">
 </p>
<table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
<tr>
<td width="79%"></td>
<td valign="bottom" width="4%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="4%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="6" align="center">
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px" align="center">
<font style="FONT-FAMILY: Times New Roman" size="1"><b>Three Months
Ended</b></font></p>
<p style="MARGIN-BOTTOM: 1px; MARGIN-TOP: 0px" align="center">
<font style="FONT-FAMILY: Times New Roman" size="1"><b>March 31,</b></font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr>
<td height="8"></td>
<td height="8" colspan="4"></td>
<td height="8" colspan="4"></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and
development</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>97,417</b></font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>  </b></font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">26,621</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">General and
administrative</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b> </b></font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>102,337</b></font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>  </b></font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">47,449</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total share-based
compensation expense</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>199,754</b></font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>  </b></font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">74,070</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
</tr>
</table>
</div>
<div>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Use of
Estimates</b></font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2">The preparation of
financial statements in conformity with generally accepted
accounting principles requires management to make estimates and
assumptions that affect the amounts reported in the financial
statements and accompanying notes. Although actual results could
differ from those estimates, management does not believe that such
differences would be material.</font></p>
</div>
<div>
<p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2"><b>1.
Organization</b></font></p>
<p style="margin-top:6px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">Intra-Cellular Therapies,
Inc. (the “Company”), through its wholly-owned
operating subsidiary, ITI, Inc. (“ITI”), is a
biopharmaceutical company focused on the discovery and clinical
development of innovative, small molecule drugs that address
underserved medical needs in neuropsychiatric and neurological
disorders by targeting intracellular signaling mechanisms within
the central nervous system (“CNS”). The Company’s
lead product candidate, ITI-007, is in late phase clinical
development as a first-in-class treatment for
schizophrenia.</font></p>
<p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">ITI was incorporated in the
State of Delaware on May 22, 2001 under the name
“Intra-Cellular Therapies, Inc.” and commenced
operations in June 2002. ITI was founded to discover and
develop drugs for the treatment of neurological and psychiatric
disorders.</font></p>
<p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">On August 29, 2013, ITI
completed a reverse merger (the “Merger”) with a public
shell company named Oneida Resources Corp. (“Oneida”).
Oneida was formed in August 2012 as a vehicle to investigate and,
if such investigation warranted, acquire a target company or
business seeking the perceived advantages of being a publicly held
corporation. In the Merger, each outstanding share of capital stock
of ITI was exchanged for 0.5 shares of common stock of Oneida, and
each outstanding option to purchase one share of ITI common stock
and each outstanding warrant to purchase one share of ITI common
stock was assumed by Oneida and became exercisable for 0.5 shares
of Oneida common stock. As a result of the Merger and related
transactions, ITI survived as a wholly-owned subsidiary of Oneida,
Oneida changed its fiscal year end from March 31 to
December 31, and Oneida changed its name to Intra-Cellular
Therapies, Inc. (the “Company”). In addition, the
Company began operating ITI and its business, and therefore ceased
being a shell company. Following the Merger and the redemption of
all then outstanding shares of Oneida at the closing of the Merger,
the former shareholders of ITI owned 100% of the shares of the
Company’s outstanding capital stock.</font></p>
<p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">In accordance with Financial
Accounting Standards Board (“FASB”), Accounting
Standards Codification (“ASC”) Topic 805, <i>Business
Combinations</i>, ITI is considered the acquirer for accounting
purposes, and has accounted for the transaction as a capital
transaction, because ITI’s former stockholders received 100%
of the voting rights in the combined entity and ITI’s senior
management represents all of the senior management of the combined
entity. Consequently, the assets and liabilities and the historical
operations that are reflected in the Company’s consolidated
financial statements are those of ITI and have been recorded at the
historical cost basis of the Company. All share and per share
amounts in the condensed consolidated financial statements and
related notes have been retrospectively adjusted to reflect the one
for 0.5 shares common stock exchange as well as the conversion of
the Notes and Series A, B, and C redeemable convertible preferred
stock of ITI.</font></p>
<p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">Immediately prior to the
Merger, on August 29, 2013, ITI sold to accredited investors
approximately $60.0 million of its shares of common stock, or
18,889,307 shares at a price of $3.1764 per share (the
“Private Placement”), which included $15.3 million in
principal and $0.8 million in accrued interest from the conversion
of ITI’s then outstanding convertible promissory notes (the
“Notes”).</font></p>
<p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">On February 5, 2014,
the Company completed a public offering of common stock in which
the Company sold 7,063,300 shares of common stock, which included
the exercise of the underwriters’ option to purchase 921,300
shares, at an offering price of $17.50 per share. After deducting
underwriting discounts, commissions and offering expenses, the net
proceeds to the Company were approximately $115.4
million.</font></p>
<p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">The Company earns license
and collaboration revenue from its significant partnership with
Takeda Pharmaceutical Company Limited (“Takeda”). In
order to further its research projects and support its
collaborations, the Company will require additional financing until
such time, if ever, that revenue streams are sufficient to generate
consistent positive cash flow from operations. Possible sources of
funds include strategic alliances, additional equity offerings,
grants and contracts, and research and development funding from
third parties.</font></p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>Loss Per Share</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
Basic net loss per common share is determined by dividing the net
loss by the weighted-average number of common shares outstanding
during the period, without consideration of common stock
equivalents. Diluted net loss per share is computed by dividing the
net loss by the weighted-average number of common stock equivalents
outstanding for the period. The treasury stock method is used to
determine the dilutive effect of the Company’s stock option
grants.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
The following common stock equivalents were excluded in the
calculation of diluted loss per share because their effect would be
anti-dilutive as applied to the loss from operations as of the
three months ended March 31, 2014 and 2013:</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 </p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
</p>
<table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
<tr>
<td width="78%"></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td valign="bottom" colspan="6" align="center">
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>Three Months Ended</b></p>
<p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>March 31,</b></p>
</td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Stock options</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">941,279</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">1,216,463</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 </p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
The following table describes the weighted-average assumptions used
for calculating the value of options granted during the three
months ended March 31, 2014:</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"><!-- Begin Table Head -->
<tr>
<td width="87%"></td>
<td valign="bottom" width="4%"></td>
<td></td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"><b>2014</b></td>
</tr>
<!-- End Table Head --><!-- Begin Table Body -->
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Dividend yield</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom" align="center"><b>0%</b></td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Expected volatility</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom" align="center"><b>80%</b></td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Weighted-average risk-free interest rate</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom" align="center"><b>2.0%</b></td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Expected term</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom" align="center"><b>6.4 years</b></td>
</tr>
</table>
<p> </p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Financial
Instruments</b></font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company considers the
recorded costs of its financial assets and liabilities, which
consist of cash equivalents, accounts receivable, accounts payable
and accrued liabilities, to approximate their fair value because of
their relatively short maturities at March 31, 2014 and
December 31, 2013. Management believes that the risks
associated with its financial instruments are minimal as the
counterparties are various corporations, financial institutions and
government agencies of high credit standing.</font></p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Deferred
Revenue</b></font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2">Cash received as prepayment
on future services is deferred and recognized as revenue as the
services are performed. The Company must remit interest on any
deferred revenue related to a governmental agency. As of
March 31, 2014 and December 31, 2013, no interest was due
as the Company did not have any deferred revenue from a government
agency.</font></p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Income
Taxes</b></font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2">Income taxes are accounted
for using the liability method. Deferred tax assets and liabilities
are recognized for the future tax consequences attributable to
differences between the financial statement carrying amounts of
existing assets and liabilities and its respective tax bases.
Deferred tax assets and liabilities are measured using enacted tax
rates expected to apply to taxable income in the year in which
those temporary differences are expected to be recovered or
settled.</font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"><font style="FONT-FAMILY: Times New Roman" size="2">The effect on deferred tax
assets and liabilities of a change in tax rates is recognized in
income in the period that includes the enactment date. Valuation
allowances are established when necessary to reduce net deferred
tax assets to the amount expected to be realized. Income tax
expense is the tax payable for the period and the change during the
period in deferred tax assets and liabilities.</font></p>
<p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company accounts for
uncertain tax positions pursuant to ASC Topic 740 (previously
included in FASB Interpretation No. 48, <i>Accounting for
Uncertainty in Income Taxes–an Interpretation of FASB
Statement No. 109)</i>. Financial statement recognition of a
tax position taken or expected to be taken in a tax return is
determined based on a more-likely-than-not threshold of that
position being sustained. If the tax position meets this threshold,
the benefit to be recognized is measured as the tax benefit having
the highest likelihood of being realized upon ultimate settlement
with the taxing authority. The Company recognizes interest accrued
related to unrecognized tax benefits and penalties in the provision
for income taxes.</font></p>
</div>
167787
-108247
3900
36220
0
-4574463
5041
738005
-168531
-4543284
3120
0
1912951
115453280
199754
4742250
108467323
-3120
-1670114
5041
-1252288
116191285
2829299
6317
0.00
The later of expiration of the last licensed patent covering a licensed product, its method of manufacture or use, the expiration of other government grants providing market exclusivity or 10 years after first commercial sale of a licensed product in such country, subject to rights of the parties to sooner terminate the agreement on certain events and the right of Takeda to unilaterally terminate the agreement upon a specified number of days' prior notice
P6Y4M24D
More than three months
Three months or less
P3Y
P5Y
P2Y
P3Y
1000000
102337
97417
168000
P3Y
400000
120000
Upon expiration of the patent rights or 15 years subsequent to the first sale of products developed through this License.
0
941279
Through the later of ten years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product.
P3Y
2014-02
0001567514
itci:TakedaPharmaceuticalCompanyLimitedMember
2014-01-01
2014-03-31
0001567514
itci:BristolMyersSquibbCompanyMember
2014-01-01
2014-03-31
0001567514
us-gaap:StockOptionMember
2014-01-01
2014-03-31
0001567514
itci:UniversityMemberus-gaap:LicensingAgreementsMember
2014-01-01
2014-03-31
0001567514
itci:TakedaPharmaceuticalCompanyLimitedMemberus-gaap:CollaborativeArrangementMember
2014-01-01
2014-03-31
0001567514
us-gaap:ResearchAndDevelopmentExpenseMember
2014-01-01
2014-03-31
0001567514
us-gaap:GeneralAndAdministrativeExpenseMember
2014-01-01
2014-03-31
0001567514
itci:UniversityMemberus-gaap:MinimumMemberus-gaap:LicensingAgreementsMember
2014-01-01
2014-03-31
0001567514
us-gaap:MinimumMember
2014-01-01
2014-03-31
0001567514
us-gaap:MaximumMember
2014-01-01
2014-03-31
0001567514
2014-01-01
2014-03-31
0001567514
us-gaap:StockOptionMember
2013-01-01
2013-03-31
0001567514
itci:UniversityMemberus-gaap:LicensingAgreementsMember
2013-01-01
2013-03-31
0001567514
itci:TakedaPharmaceuticalCompanyLimitedMemberus-gaap:CollaborativeArrangementMember
2013-01-01
2013-03-31
0001567514
us-gaap:ResearchAndDevelopmentExpenseMember
2013-01-01
2013-03-31
0001567514
us-gaap:GeneralAndAdministrativeExpenseMember
2013-01-01
2013-03-31
0001567514
2013-01-01
2013-03-31
0001567514
2012-04-01
2013-03-31
0001567514
itci:BristolMyersSquibbCompanyMember
2013-12-01
2013-12-31
0001567514
2014-02-04
2014-02-05
0001567514
us-gaap:PrivatePlacementMember
2013-08-28
2013-08-29
0001567514
itci:OneidaResourcesCorpMember
2013-08-28
2013-08-29
0001567514
itci:BristolMyersSquibbCompanyMember
2013-12-31
0001567514
us-gaap:FurnitureAndFixturesMember
2013-12-31
0001567514
us-gaap:ComputerEquipmentMember
2013-12-31
0001567514
us-gaap:EquipmentMember
2013-12-31
0001567514
us-gaap:LeaseholdImprovementsMember
2013-12-31
0001567514
us-gaap:FairValueInputsLevel3Member
2013-12-31
0001567514
us-gaap:FairValueInputsLevel2Member
2013-12-31
0001567514
2013-12-31
0001567514
2012-12-31
0001567514
itci:TwoThousandThirteenEquityIncentivePlanMember
2014-03-31
0001567514
us-gaap:FurnitureAndFixturesMember
2014-03-31
0001567514
us-gaap:ComputerEquipmentMember
2014-03-31
0001567514
us-gaap:EquipmentMember
2014-03-31
0001567514
us-gaap:LeaseholdImprovementsMember
2014-03-31
0001567514
us-gaap:FairValueInputsLevel3Member
2014-03-31
0001567514
us-gaap:FairValueInputsLevel2Member
2014-03-31
0001567514
itci:TakedaPharmaceuticalCompanyLimitedMemberus-gaap:CollaborativeArrangementMember
2014-03-31
0001567514
itci:TakedaPharmaceuticalCompanyLimitedMemberus-gaap:MaximumMemberus-gaap:CollaborativeArrangementProductAgreementMember
2014-03-31
0001567514
itci:TakedaPharmaceuticalCompanyLimitedMemberus-gaap:MaximumMemberus-gaap:CollaborativeArrangementCopromotionMember
2014-03-31
0001567514
2014-03-31
0001567514
itci:TakedaPharmaceuticalCompanyLimitedMemberus-gaap:CollaborativeArrangementMember
2013-03-31
0001567514
2013-03-31
0001567514
2014-04-30
0001567514
2014-02-05
0001567514
itci:TwoThousandThirteenEquityIncentivePlanMember
2014-01-31
0001567514
us-gaap:PrivatePlacementMember
2013-08-29
0001567514
itci:OneidaResourcesCorpMember
2013-08-29
pure
iso4217:USD
shares
iso4217:USD
shares